Suchergebnisse - "Agbarya, Abed"

PubPharm (55)

31

Oncology Treatments during the COVID-19 Pandemic in Israel : the ONCOR Study

enthalten in: The Israel Medical Association journal : IMAJ | 2021

von Hirsh-Yechezkel, G. | Chetrit, A. | Ben Avraham, S. | +18

32

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future

enthalten in: Journal of clinical medicine | 2021

von Szeto, C. | Shalata, W. | Yakobson, A. | +1

33

Automatic localization of the prostatic urethra for image guided radiation therapy

enthalten in: Technical innovations & patient support in radiation oncology | 2021

von Nasser, N. | Klein, J. | Fenig, E. | +1

34

Encephalitis Induced by Durvalumab During Treatment of Metastatic Small-Cell Lung Cancer : Illustrative Case and Review of the Literature

enthalten in: Journal of immunotherapy (Hagerstown, Md. : 1997) | 2021

von Shechtman, Y. | Shalata, W. | Khoury, R. | +3

35

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future

enthalten in: Preprints.org | 2021

von Shalata, W. | Jacob, B. | Agbarya, A.

36

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10

37

Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs

enthalten in: Cancers | 2021

von Agbarya, A. | Sarel, I. | Ziv-Baran, T. | +14

38

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future

enthalten in: Cancers | 2021

von Shalata, W. | Jacob, B. | Agbarya, A.

39

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-$ ABL1^{T315I} $ and BCR-$ ABL1^{T315I-E255K} $

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10

40

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-$ ABL1^{T315I} $ and BCR-$ ABL1^{T315I-E255K} $

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10